Burrows Scott L sold $717K of SYRE
Burrows Scott L (Chief Financial Officer) sold 7,500 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $95.57 ($95.21–$97.10, $0.72M total) across 3 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale details (shares, price range, total value) executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure makes it less likely to be a new fundamental signal.
What to watch
The filing does not disclose reasons for the sale, and the transaction size is not large enough here to infer a major change without corroborating news.
Background
The article is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, Inc.
Ticker impact
Spyre Therapeutics CFO Burrows Scott L sold about 7,500 shares in open-market transactions under a 10b5-1 plan, totaling $716,771.
Likely limited near-term impact; any effect would be modest and short-lived unless followed by additional disclosures.
Form 4 shows a pre-arranged 10b5-1 plan and an open-market sale by an officer, which typically reduces the likelihood of immediate, information-driven repricing.
Market effects
Minimal sector read-through; insider sales under 10b5-1 are generally not sector-moving.
None indicated.
None indicated.
Counterpoint
The sale could be purely liquidity-driven under a scheduled 10b5-1 plan, so it may not reflect bearish expectations.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBurrows Scott L
Chief Financial Officer who sold shares under a 10b5-1 plan.
